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This meta-analysis aims to combine and analyze
randomized clinical trials comparing computed
tomography lung screening (CTLS) versus either no
screening (NS) or chest x-ray (CXR) in subjects with
cigarette smoking history, to provide a precise and
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RESULTS
CONCLUSION
Data from all published randomized trials comparing
CTLS versus either NS or CXR in a highly tobacco-
exposed population were collected, according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines. Subgroup analyses by
comparator (NS or CXR) were performed. Pooled risk
ratio (RR) and relative 95% CIs were calculated for
dichotomous outcomes. The certainty of the evidence
was assessed using the GRADE approach.
Nine eligible trials (88,497 patients) were included.
Pooled analysis showed that CTLS is associated with: a
significant reduction of lung cancer–related mortality
(overall RR, 0.87; 95% CI, 0.78 to 0.98; NS RR, 0.80; 95%
CI, 0.69 to 0.92); a significant increase of early-stage
tumors diagnosis (overall RR, 2.84; 95% CI 1.76 to 4.58;
NS RR, 3.33; 95% CI, 2.27 to 4.89; CXR RR, 1.52; 95% CI,
1.04 to 2.23); a significant decrease of late-stage
tumors diagnosis (overall RR, 0.75; 95% CI, 0.68 to 0.83;
NS RR, 0.67; 95% CI, 0.56 to 0.80); a significant increase
of resectability rate (NS RR, 2.57; 95% CI, 1.76 to 3.74);
a nonsignificant reduction of all-cause mortality
(overall RR, 0.99; 95% CI, 0.94 to 1.05); and a significant
increase of overdiagnosis rate (NS, 38%; 95% CI, 14 to
63). The analysis of lung cancer–related mortality by
sex revealed nonsignificant differences between men
and women (P = .21; I-squared = 33.6%).
Despite there still being uncertainty about
overdiagnosis estimate, this meta-analysis suggested
that the CTLS benefits outweigh harms, in subjects
with cigarette smoking history, ultimately supporting
the systematic implementation of lung cancer
screening worldwide.
© 2021 by American Society of Clinical Oncology
CONTEXT
Key Objective
This meta-analysis provides an updated estimation of
the benefits and harms associated with computed
tomography lung screening (CTLS) in subjects with
cigarette smoking history, which may serve as scientific
support for evidence-based guidelines.
Knowledge Generated
CTLS was associated with a significant 20% reduction of
lung cancer–related mortality, without differences
between men and women. A significant increase in
early-stage tumors diagnosis and resectability rate
along with a decrease in late-stage tumors diagnosis
was observed. A significant increase of the
overdiagnosis rate was reported too.
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